Vor Biopharma

Vor Bio is developing telitacicept, a novel dual-target fusion protein, to address serious autoantibody-driven conditions worldwide. 

Domain
Healthcare
Status
IPO’d/​Acquired
IPO Date
2021
Stage of Initial Investment
Series A
Initial Investment Year
2019
Vor Hover Image